Bridging the Gap Between FDA Breakthrough and Payer Coverage

Regenerative medicine is currently trapped in the "Inference Gap." RegenMed provides the decentralized infrastructure to capture Deterministic Evidence post-launch — enabling insurers to authorize high-cost therapies with the security of a longitudinal verification layer.
Go Deeper

The "Twin Sins" of Regenerative Coverage

The Problem: Traditional payer rulebooks are "static." They rely on "Data Exhaust" — billing codes and administrative claims — which cannot capture the nuanced clinical mastery required to successfuly deploy regenerative therapies.
The Consequences of Low-Fidelity Data:
The Sin of Omission
FDA-approved breakthroughs are denied coverage because legacy claims feeds cannot prove the longitudinal cost-offsets (e.g., avoiding future fusions or chronic opioid use).
The Sin of Commission
Carriers continue to fund low-value, palliative care because it fits within the existing "pre-negotiated" codes, even when more effective regenerative options exist.
Actuarial Uncertainty
Without high-fidelity outcomes captured at the source, insurers cannot accurately predict the ROI of regenerative investments, leading to broad-spectrum denials.

Engineering the Verification Layer

The Solution: The Solution:  We replace "trust-based" authorization with engineering solutions. By Structuring at the Source, we provide the deterministic evidence required to adjudicate the value of high-cost therapies in real-time.
The Validation Rails:
Deterministic Integrity
Outcomes are minted at the point of care, providing unrefutable proof of functional recovery that overrides the ambiguity of legacy data.
Longitudinal Outcome Adjudication
Track the real-world effectiveness of regenerative therapies over 24+ months, ensuring that coverage is tied to sustained clinical success.
Zero-Lift Physician Compliance
Clinicians capture high-fidelity evidence as a byproduct of their existing workflow, ensuring the Payer receives the data they need without increasing provider burnout.

Individualized Value

Treating the Patient, Not the Code

Utilize high-fidelity data to identify the specific patient cohorts who derive the most value from regenerative interventions, allowing for more precise (and profitable) authorization.

Scientific Sovereignty

Empower your network’s top physicians to define the evidence-based standards for regenerative care, ensuring that the "fundamentals" of medicine drive coverage, not administrative inertia.

Sustainability of Innovation

Protect the future of medical breakthroughs by providing a sustainable, verifiable path to market scale that satisfies both the FDA and the Carrier.

The Infrastructure for Verifiable Healthcare

1.4m+
Structured Datapoints
75+
Active Specialty Protocols
3X
3X
YoY Coverage Success for Innovative Devices
The Evidence Vault
Access our "Technical Brief on Regenerative Adjudication" and the "White Paper on Eliminating Value Uncertainty in Biologic Interventions".
Visit The Vault

Not finding the info you need?

EMAIL US

Have a specific question? Write to us at circles@rgnmed.com and we'll respond promptly with the details you need.
Email us

BOOK A MEETING

Prefer a personal chat? Schedule a quick call with our team to get tailored advice and answers in real time.
Book a meeting
Scroll Up Arrow